IL33 and Alzheimer disease: Importantly, consistent with the phenotype of IL-33 transgenic mice and AD patients, Dfb-treated HrasG12S/+ mice showed AD-like skin lesions, reduced claudin-1 expression, increased IL-33 expression, hyperproliferation of p-ERK-positive epidermal cells, and increased ILC2 production.